Roger Levy

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/666710/roger-levy-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

 100
 5,506
 29
 73

 papers
 citations
 h-index
 g-index

 114
 6,662
 5.2
 4.95

 ext. papers
 ext. citations
 avg, IF
 L-index

#	Paper	IF	Citations
100	Identifying Barriers to Enrollment in Patient Pregnancy Registries: Building Evidence Through Crowdsourcing. <i>JMIR Formative Research</i> , 2022 , 6, e30573	2.5	
99	The SLICC/ACR Damage Index (SDI) may predict adverse obstetric events in patients with systemic lupus erythematosus. <i>Lupus</i> , 2021 , 30, 1966-1972	2.6	
98	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. <i>Arthritis Care and Research</i> , 2021 , 73, 1490-150	1 1 .7	13
97	16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome. <i>Lupus</i> , 2021 , 30, 1314-1326	2.6	2
96	Pulmonary hypertension in systemic sclerosis: diagnosis by systematic screening and prognosis after three years follow-up. <i>BMC Pulmonary Medicine</i> , 2021 , 21, 251	3.5	1
95	Soluble Flt-1, Placental Growth Factor, and Vascular Endothelial Growth Factor Serum Levels to Differentiate Between Active Lupus Nephritis During Pregnancy and Preeclampsia. <i>Arthritis Care and Research</i> , 2021 , 73, 717-721	4.7	7
94	Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial. <i>Lancet Rheumatology, The</i> , 2021 , 3, e122-e130	14.2	9
93	10 Years of belimumab experience: What have we learnt?. <i>Lupus</i> , 2021 , 30, 1705-1721	2.6	10
92	The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis. <i>Arthritis Research and Therapy</i> , 2020 , 22, 102	5.7	10
91	Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression. <i>Lupus</i> , 2020 , 29, 1011-1020	2.6	20
90	Epidemiologic Features of Systemic Vasculitides in the Southeast Region of Brazil: Hospital-Based Survey. <i>Journal of Clinical Rheumatology</i> , 2020 , 26, S106-S110	1.1	2
89	Characteristics of Antiphospholipid Antibody Positive Patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking. <i>Arthritis Care and Research</i> , 2020 ,	4.7	13
88	Ophthalmologic manifestations in primary antiphospholipid syndrome patients: A cross-sectional analysis of a primary antiphospholipid syndrome cohort (APS-Rio) and systematic review of the literature. <i>Lupus</i> , 2020 , 29, 1528-1543	2.6	7
87	Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension. <i>Rheumatology</i> , 2020 , 59, 281-291	3.9	28
86	The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. <i>Thrombosis Research</i> , 2019 , 175, 32-36	8.2	12
85	Use of synthetic and biologic DMARDs during pregnancy. <i>Expert Review of Clinical Immunology</i> , 2019 , 15, 27-39	5.1	6
84	The interplay between tuberculosis and systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2018 , 30, 395-402	5.3	18

(2016-2018)

83	New and upcoming treatments in antiphospholipid syndrome: A comprehensive review. <i>Pharmacological Research</i> , 2018 , 133, 108-120	10.2	6
82	First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL,)-Pan-American League of Associations of Rheumatology (PANLAR). <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1549-1557	2.4	57
81	Computed tomography trachea volumetry in patients with scleroderma: Association with clinical and functional findings. <i>PLoS ONE</i> , 2018 , 13, e0200754	3.7	2
80	Challenging cases in rheumatic pregnancies. <i>Rheumatology</i> , 2018 , 57, v18-v25	3.9	1
79	Antiphospholipid antibodies in epilepsy: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2018 , 17, 755-767	13.6	14
78	CCL2, CXCL8, CXCL9 and CXCL10 serum levels increase with age but are not altered by treatment with hydroxychloroquine in patients with osteoarthritis of the knees. <i>International Journal of Rheumatic Diseases</i> , 2017 , 20, 1958-1964	2.3	15
77	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 554-561	2.4	175
76	History, Classification, and Subsets of the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017 , 1-16	0.3	1
75	Ocular involvement in patients with spondyloarthritis. <i>Rheumatology</i> , 2017 , 56, 2060-2067	3.9	14
74	Recommendations of the Brazilian Society of Rheumatology for the induction therapy of ANCA-associated vasculitis. <i>Revista Brasileira De Reumatologia</i> , 2017 , 57 Suppl 2, 484-496		8
73	Rapidly progressive diffuse systemic sclerosis after local vitamins A, D and E complex injections: literature review and report of two cases. <i>Immunologic Research</i> , 2017 , 65, 285-292	4.3	2
72	Update on antiphospholipid antibody syndrome. <i>Revista Da Associa</i> Malica Brasileira, 2017 , 63, 994-999	1.4	14
71	Catastrophic antiphospholipid syndrome: A case with unusual findings revealed in autopsy and a brief literature update. <i>European Journal of Rheumatology</i> , 2017 , 4, 281-283	1.7	1
70	Definition and Epidemiology of Antiphospholipid Syndrome 2017 , 147-169		1
69	Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. <i>Clinical Rheumatology</i> , 2016 , 35, 801-5	3.9	50
68	Biology of anti-TNF agents in immune-mediated inflammatory diseases: therapeutic implications. <i>Immunotherapy</i> , 2016 , 8, 1427-1436	3.8	8
67	Infliximab-induced autoantibodies: a multicenter study. Clinical Rheumatology, 2016, 35, 325-32	3.9	20
66	The autoimmune diseases of the eyes. <i>Autoimmunity Reviews</i> , 2016 , 15, 258-71	13.6	26

65	The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 285-90	7	48
64	Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis. <i>Anais Brasileiros De Dermatologia</i> , 2016 , 91, 137-139	1.6	10
63	Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation. <i>Autoimmunity Reviews</i> , 2016 , 15, 955-63	13.6	58
62	The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. <i>Autoimmunity Reviews</i> , 2015 , 14, 401-14	13.6	136
61	Yellow Fever Vaccine and Autoimmunity 2015 , 135-140		2
60	Understanding and Managing Pregnancy in Patients with Lupus. <i>Autoimmune Diseases</i> , 2015 , 2015, 9434	49.0)	37
59	Antiphospholipid Antibodies and Antiphospholipid Syndrome during Pregnancy: Diagnostic Concepts. <i>Frontiers in Immunology</i> , 2015 , 6, 205	8.4	20
58	Putting the value into biosimilar decision making: the judgment value criteria. <i>Autoimmunity Reviews</i> , 2014 , 13, 678-84	13.6	18
57	Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment?. <i>Current Rheumatology Reports</i> , 2014 , 16, 403	4.9	32
56	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 958-67	2.4	388
55	14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. <i>Autoimmunity Reviews</i> , 2014 , 13, 685-96	13.6	248
54	Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 838-44	2.4	98
53	The use of angiogenic and antiangiogenic factors in the differential diagnosis of pre-eclampsia, antiphospholipid syndrome nephropathy and lupus nephritis. <i>Lupus</i> , 2014 , 23, 1299-301	2.6	17
52	Lepromatous leprosy mimicking systemic lupus erythematosus: a clinical pathology conference held by the division of rheumatology at hospital for special surgery. <i>HSS Journal</i> , 2014 , 10, 286-91	2	8
51	Relevance of different results of different anti-double-stranded DNA assays in reporting clinical studies: comment on the article by Petri et al. Reply. <i>Arthritis and Rheumatology</i> , 2014 , 66, 480	9.5	
50	Cardiovascular risk factors in the antiphospholipid syndrome. <i>Journal of Immunology Research</i> , 2014 , 2014, 621270	4.5	20
49	Changes in anti-citrullinated protein antibody titers following treatment with infliximab for rheumatoid arthritis. <i>Israel Medical Association Journal</i> , 2014 , 16, 17-9	0.9	2
48	Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2143-53		119

(2009-2013)

47	Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. <i>Lupus</i> , 2013 , 22, 144-54	2.6	92
46	Systematic review of infliximab-induced autoantibodies and systemic lupus erythematosus. <i>Revista Brasileira De Reumatologia</i> , 2013 , 53, 358-364		1
45	Diretrizes para o tratamento da sfidrome do anticorpo antifosfolipfieo. <i>Revista Brasileira De Reumatologia</i> , 2013 , 53, 184-192		13
44	Guidelines for the treatment of antiphospholipid syndrome. <i>Revista Brasileira De Reumatologia</i> , 2013 , 53, 184-192		3
43	RevisB sistemBica da induB de autoanticorpos e lpus eritematoso pelo infliximabe. <i>Revista Brasileira De Reumatologia</i> , 2013 , 53, 358-364		4
42	Translation, cross-cultural adaptation and validation of the Brazilian version of the Nonarthritic Hip Score. <i>Sao Paulo Medical Journal</i> , 2013 , 131, 244-51	1.6	8
41	Management of obstetric antiphospholipid syndrome. Current Rheumatology Reports, 2012, 14, 79-86	4.9	23
40	The multiple autoimmune syndromes. A clue for the autoimmune tautology. <i>Clinical Reviews in Allergy and Immunology</i> , 2012 , 43, 256-64	12.3	48
39	APS ACTION in Brazil. Revista Brasileira De Reumatologia, 2012 , 52, 811-4		
38	Pregnancy may aggravate arterial hypertension in women with Takayasu arteritis. <i>Israel Medical Association Journal</i> , 2012 , 14, 724-8	0.9	9
38 37		0.9	9
	Association Journal, 2012, 14, 724-8 Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a		
37	Association Journal, 2012, 14, 724-8 Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet, The, 2011, 377, 721-31 Systemic sclerosis-associated interstitial pneumonia: evaluation of pulmonary function over a	40	1206
37 36	Association Journal, 2012, 14, 724-8 Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet, The, 2011, 377, 721-31 Systemic sclerosis-associated interstitial pneumonia: evaluation of pulmonary function over a five-year period. Jornal Brasileiro De Pneumologia, 2011, 37, 144-51	40	1206 9
37 36 35	Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2011 , 377, 721-31 Systemic sclerosis-associated interstitial pneumonia: evaluation of pulmonary function over a five-year period. <i>Jornal Brasileiro De Pneumologia</i> , 2011 , 37, 144-51 Cutting-edge issues in autoimmune uveitis. <i>Clinical Reviews in Allergy and Immunology</i> , 2011 , 41, 214-23	40 1.1 12.3	1206 9 15
37 36 35 34	Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet, The, 2011, 377, 721-31 Systemic sclerosis-associated interstitial pneumonia: evaluation of pulmonary function over a five-year period. Jornal Brasileiro De Pneumologia, 2011, 37, 144-51 Cutting-edge issues in autoimmune uveitis. Clinical Reviews in Allergy and Immunology, 2011, 41, 214-23 Antiphospholipid Syndrome Clinical Research Task Force report. Lupus, 2011, 20, 219-24 Increased expression of tissue factor and protease-activated receptor-1 does not correlate with thrombosis in human lung adenocarcinoma. Brazilian Journal of Medical and Biological Research,	40 1.1 12.3	1206 9 15 25
37 36 35 34 33	Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet, The, 2011, 377, 721-31 Systemic sclerosis-associated interstitial pneumonia: evaluation of pulmonary function over a five-year period. Jornal Brasileiro De Pneumologia, 2011, 37, 144-51 Cutting-edge issues in autoimmune uveitis. Clinical Reviews in Allergy and Immunology, 2011, 41, 214-23 Antiphospholipid Syndrome Clinical Research Task Force report. Lupus, 2011, 20, 219-24 Increased expression of tissue factor and protease-activated receptor-1 does not correlate with thrombosis in human lung adenocarcinoma. Brazilian Journal of Medical and Biological Research, 2010, 43, 403-8	40 1.1 12.3 2.6	1206 9 15 25

29	Lung adenocarcinoma and antiphospholipid antibodies. <i>Autoimmunity Reviews</i> , 2009 , 8, 529-32	13.6	10
28	Management of patients with rheumatoid arthritis in Latin America: a consensus position paper from Pan-American League of Associations of Rheumatology and Grupo Latino Americano De Estudio De Artritis Reumatoide. <i>Journal of Clinical Rheumatology</i> , 2009 , 15, 203-10	1.1	31
27	Treatment of Raynaudß phenomenon. <i>Autoimmunity Reviews</i> , 2008 , 8, 62-8	13.6	28
26	Amputation of digits or limbs in patients with antiphospholipid syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2008 , 38, 124-31	5.3	30
25	Infections and autoimmunity: a panorama. Clinical Reviews in Allergy and Immunology, 2008, 34, 283-99	12.3	46
24	The impact of Arthritis & Rheumatism in Latin America. <i>Arthritis and Rheumatism</i> , 2008 , 58, S145		
23	Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. <i>Arthritis and Rheumatism</i> , 2007 , 56, 2382-91		284
22	Lupus anticoagulant activity as a thrombosis risk factor in lung adenocarcinoma patients. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1107, 51-5	6.5	5
21	Primary antiphospholipid nephropathy beginning during pregnancy. <i>Rheumatology International</i> , 2007 , 27, 289-93	3.6	5
20	Antiphospholipid syndrome and cognition. <i>Clinical Reviews in Allergy and Immunology</i> , 2007 , 32, 188-91	12.3	9
19	Correlation of Thrombosis and Prothrombotic Markers with Outcome in Lung Adenocarcinoma Patients: A Prospective Study <i>Blood</i> , 2007 , 110, 3985-3985	2.2	1
18	Contractile cells and fibrillin-1 distribution is disturbed in terminal villi of placentae from patients with preeclampsia and systemic lupus erythematosus. <i>Placenta</i> , 2006 , 27, 234-43	3.4	3
17	Anti-inflammatory and immunosuppressive drugs and reproduction. <i>Arthritis Research and Therapy</i> , 2006 , 8, 209	5.7	373
16	Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. <i>American Journal of Medicine</i> , 2006 , 119, 255-66	2.4	259
15	Use of Anti-Rheumatic Drugs in Pregnancy. <i>Handbook of Systemic Autoimmune Diseases</i> , 2005 , 4, 101-11	0 0.3	1
14	I latin american congress of autoimmunity galapagosSeptember 15-18. <i>Autoimmunity Reviews</i> , 2004 , 3, 76-87	13.6	
13	An adapted ELISA method for differentiating pathogenic from nonpathogenic aPL by a beta 2 glycoprotein I dependency anticardiolipin assay. <i>Thrombosis Research</i> , 2004 , 114, 573-7	8.2	21
12	Treatment of pregnant patients with antiphospholipid syndrome. <i>Lupus</i> , 2003 , 12, 524-9	2.6	95

LIST OF PUBLICATIONS

11	Prevention of thrombosis during pregnancy. Israel Medical Association Journal, 2002, 4, 794-7	0.9	3
10	Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. <i>Lupus</i> , 2001 , 10, 401-4	2.6	275
9	Mechanisms of pregnancy loss in antiphospholipid syndrome. <i>Clinical Obstetrics and Gynecology</i> , 2001 , 44, 11-9	1.7	43
8	Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. <i>Medicine</i> (United States), 1998 , 77, 195-207	1.8	374
7	Clinical manifestations of the aPL syndrome. <i>Lupus</i> , 1996 , 5, 393-7	2.6	16
6	Phospholipid binding of antiphospholipid antibodies and placental anticoagulant protein. <i>Journal of Clinical Immunology</i> , 1992 , 12, 27-35	5.7	71
5	Fatty acid chain is a critical epitope for antiphospholipid antibody. <i>Journal of Clinical Immunology</i> , 1990 , 10, 141-5	5.7	28
4	Lysophosphatidylethanolamine is the antigen to which apparent antibody to phosphatidylethanolamine binds. <i>Journal of Clinical Immunology</i> , 1990 , 10, 200-3	5.7	23
3	Characteristics of high-titer IgG antiphospholipid antibody in systemic lupus erythematosus patients with and without fetal death. <i>Arthritis and Rheumatism</i> , 1990 , 33, 501-4		44
2	Characteristics of IgG antiphospholipid antibodies in patients with systemic lupus erythematosus and syphilis. <i>Journal of Rheumatology</i> , 1990 , 17, 1036-41	4.1	30
1	IgG but not IgM anti-phospholipid antibody binding is temperature dependent. <i>Journal of Clinical Immunology</i> , 1988 , 8, 188-92	5.7	29